Wells Fargo Supports Emergent BioSolutions NARCAN Buy
Emergent BioSolutions will acquire Adapt Pharma and its flagship product NARCAN nasal spray. Wells Fargo will provide $600 million in new debt financing to support the acquisition.
August 31, 2018
Adapt Pharma | Emergent BioSolutions | NARCAN | wells fargo
ABF Journal